Clinical Trials Browser

Phase 2 × Esophageal Neoplasms × durvalumab × Clear all

NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

450 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT03777813 2025-11-18

ARION

Phase 2 Completed

112 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms

NCT06290505 2025-07-23

PALEO

Phase 2 Recruiting

54 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT03653052 2025-04-24

CALIBRATION

Phase 2 Active not recruiting

18 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT02639065 2023-09-25

A Study of Durvalumab (MEDI4736) in Esophageal Cancer

Phase 2 Completed

39 enrolled 12 charts

Gastrointestinal

Esophageal Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02520453 2019-12-09

Adjuvant Durvalumab for Esophageal Cancer

Phase 2 Unknown

86 enrolled

Gastrointestinal

Esophageal Neoplasms